Literature DB >> 10708314

Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates.

E Dadachova1, L L Chappell, M W Brechbiel.   

Abstract

A simple spectrophotometric assay for determination of bifunctional polyazacarboxylate-macrocyclic ligands of different sizes that are conjugated to proteins has been developed for: 12-membered macrocycle DOTA (2-[4-nitrobenzyl]-1, 4, 7, 10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) and analogs, the 15-membered PEPA macrocycle (2-[4-nitrobenzyl]-1,4,7,10,13-pentaazacyclopentadecane-N,N',N'',N ''',N''''-pentaacetic acid), and the large 18-membered macrocycle HEHA (1,4,7,10,13,16-hexaazacyclooctadecane-N,N',N'',N''',N'''',N'''''- hexaacetic acid). The method is based on titration of the blue-colored 1:1 Pb(II)-Arsenazo II (AAIII) complex with the polyazacarboxylate macrocyclic ligand in the concentration range of 0-2.5 microM, wherein color change occurring upon transchelation of the Pb(II) from the AAIII to the polyazamacrocyclic ligand is monitored at 656 nm. The assay is performed at ambient temperature within 20 min without any interfering interaction between the protein and Pb(II)-AA(III) complex. Thus, this method also provides a ligand-to-protein ratio (L/P ratio) that reflects the effective number of ligands per protein molecule available to radiolabeling. The method is not suitable for 14-membered TETA macrocycle (2-[4-nitrobenzyl]-1, 4, 8, 11-tetraazacyclotetradecane N,N',N'',N'''-tetraacetic acid) because of low stability constant of Pb(II)-TETA complex. The method is rapid, simple and may be customized for other polyazacarboxylate macrocyclic ligands.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10708314     DOI: 10.1016/s0969-8051(99)00054-2

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  28 in total

1.  Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.

Authors:  Marc Hens; Ganesan Vaidyanathan; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2010-10       Impact factor: 2.408

2.  Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

3.  Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.

Authors:  C A S Regino; K J Wong; D E Milenic; E H Holmes; K Garmestani; P L Choyke; M W Brechbiel
Journal:  Curr Radiopharm       Date:  2009-01

4.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Authors:  Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2018-06       Impact factor: 3.099

5.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Martin W Brechbiel
Journal:  MAbs       Date:  2015       Impact factor: 5.857

6.  PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.

Authors:  Tapan K Nayak; Kayhan Garmestani; Diane E Milenic; Martin W Brechbiel
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

7.  Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.

Authors:  Mamta Dadwal; Chi Soo Kang; Hyun A Song; Xiang Sun; Anzhi Dai; Kwamena E Baidoo; Martin W Brechbiel; Hyun-Soon Chong
Journal:  Bioorg Med Chem Lett       Date:  2011-07-07       Impact factor: 2.823

8.  B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.

Authors:  Benjamin B Kasten; Rebecca C Arend; Ashwini A Katre; Harrison Kim; Jinda Fan; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum
Journal:  Nucl Med Biol       Date:  2017-01-10       Impact factor: 2.408

9.  (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Mol Cancer Ther       Date:  2012-01-11       Impact factor: 6.261

10.  Methodology for labeling proteins and peptides with lead-212 (212Pb).

Authors:  Kwamena E Baidoo; Diane E Milenic; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2013-04-17       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.